Our results suggest that targeting EGFR with clinical inhibitors could decrease telomerase activity in a tumor-specific manner, via decreased activity of the mutant TERTp. However, the EGFR inhibitor-induced telomerase reduction is unlikely on its own to have a strong and sustained antitumor effect. This evidence concerns the gene EGFR and neoplasm.